Phase 2
N=10
Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation
Cardiac Arrest · Sudden Cardiac Arrest
Bottom Line
View on ClinicalTrials.gov: NCT01319110 ↗Enrolled (actual)
10
Serious AEs
40.0%
Results posted
Apr 2017
Primary outcome: Primary: Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients — 0.706; 0.66 ug/mL
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Coenzyme Q10 (Drug); Placebo (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Beth Israel Deaconess Medical Center
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevalence of Low Serum CoQ10 Levels in Cardiac Arrest Patients |
0.706; 0.66 | — |
| SECONDARY Comparison of Serum CoQ10 Levels Randomized to Supplementation vs. Placebo |
— | — |
Summary
Specific Aim #1: To determine if levels of CoQ10 are low post-cardiac arrest (CA). We will perform a prospective trial with the primary endpoint of describing the prevalence of low serum CoQ10 levels.
Specific Aim #2: To determine if CoQ10 levels in post-CA patients can be increased with the administration of exogenous CoQ10.. We will perform a randomized control trial (RCT) of post-CA patients with the secondary endpoint of comparing CoQ10 levels among those randomized to CoQ10 supplementation vs placebo.
Eligibility Criteria
Inclusion Criteria
- Adult patients (age > 18 years)
- Comatose after CA with subsequent return of spontaneous circulation
Exclusion Criteria
- Comatose status prior to CA
- CoQ10 therapy within one month prior to CA
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT01319110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.